File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former

TitleEnhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former
Authors
KeywordsCyclosporine A
Dissolution
Dry powder aerosol
Mannitol
Nanoparticles
Pulmonary drug delivery
Issue Date2011
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ijpharm
Citation
International Journal Of Pharmaceutics, 2011, v. 420 n. 1, p. 34-42 How to Cite?
AbstractThis study aims to improve the dissolution of inhalable cyclosporine A nanoparticles by formulating the drug with mannitol as a hydrophilic nano-matrix former. The effect of mannitol content on the aerosol performance of the nano-matrix particles was also examined. Cyclosporine A nanosuspensions were produced by anti-solvent precipitation using a multi-inlet vortex mixer. Various amounts of mannitol were dissolved into the suspensions before spray drying to obtain micron-sized aggregates (nano-matrix powders). Dissolution properties of the powders in an aqueous medium, with the drug content, aggregate size distribution, surface roughness, physicochemical properties and aerosol performance were determined. The powders contained amorphous cyclosporine A and α-crystalline mannitol, with drug content being very close to the theoretical doses. Inclusion of mannitol enhanced the dissolution rate of the drug, without significantly affecting the aggregate size distribution, surface roughness and aerosol performance. This formulation approach may be applicable to improving the dissolution rate and bioavailability of hydrophobic drugs. © 2011 Elsevier B.V.
Persistent Identifierhttp://hdl.handle.net/10722/159774
ISSN
2023 Impact Factor: 5.3
2023 SCImago Journal Rankings: 0.954
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYamasaki, Ken_HK
dc.contributor.authorKwok, PCLen_HK
dc.contributor.authorFukushige, Ken_HK
dc.contributor.authorPrud'Homme, RKen_HK
dc.contributor.authorChan, HKen_HK
dc.date.accessioned2012-08-16T05:56:16Z-
dc.date.available2012-08-16T05:56:16Z-
dc.date.issued2011en_HK
dc.identifier.citationInternational Journal Of Pharmaceutics, 2011, v. 420 n. 1, p. 34-42en_HK
dc.identifier.issn0378-5173en_HK
dc.identifier.urihttp://hdl.handle.net/10722/159774-
dc.description.abstractThis study aims to improve the dissolution of inhalable cyclosporine A nanoparticles by formulating the drug with mannitol as a hydrophilic nano-matrix former. The effect of mannitol content on the aerosol performance of the nano-matrix particles was also examined. Cyclosporine A nanosuspensions were produced by anti-solvent precipitation using a multi-inlet vortex mixer. Various amounts of mannitol were dissolved into the suspensions before spray drying to obtain micron-sized aggregates (nano-matrix powders). Dissolution properties of the powders in an aqueous medium, with the drug content, aggregate size distribution, surface roughness, physicochemical properties and aerosol performance were determined. The powders contained amorphous cyclosporine A and α-crystalline mannitol, with drug content being very close to the theoretical doses. Inclusion of mannitol enhanced the dissolution rate of the drug, without significantly affecting the aggregate size distribution, surface roughness and aerosol performance. This formulation approach may be applicable to improving the dissolution rate and bioavailability of hydrophobic drugs. © 2011 Elsevier B.V.en_HK
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ijpharmen_HK
dc.relation.ispartofInternational Journal of Pharmaceuticsen_HK
dc.subjectCyclosporine A-
dc.subjectDissolution-
dc.subjectDry powder aerosol-
dc.subjectMannitol-
dc.subjectNanoparticles-
dc.subjectPulmonary drug delivery-
dc.subject.meshAdministration, Inhalationen_HK
dc.subject.meshAerosolsen_HK
dc.subject.meshChemical Precipitationen_HK
dc.subject.meshChemistry, Pharmaceuticalen_HK
dc.subject.meshCrystallizationen_HK
dc.subject.meshCyclosporine - administration & dosage - chemistryen_HK
dc.subject.meshDrug Carriersen_HK
dc.subject.meshDrug Compoundingen_HK
dc.subject.meshHydrophobic and Hydrophilic Interactionsen_HK
dc.subject.meshImmunosuppressive Agents - administration & dosage - chemistryen_HK
dc.subject.meshKineticsen_HK
dc.subject.meshMannitol - chemistryen_HK
dc.subject.meshNanoparticlesen_HK
dc.subject.meshNanotechnologyen_HK
dc.subject.meshPowdersen_HK
dc.subject.meshSolubilityen_HK
dc.subject.meshSurface Propertiesen_HK
dc.subject.meshTechnology, Pharmaceutical - methodsen_HK
dc.titleEnhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix formeren_HK
dc.typeArticleen_HK
dc.identifier.emailKwok, PCL: pclkwok@hku.hken_HK
dc.identifier.authorityKwok, PCL=rp01540en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ijpharm.2011.08.010en_HK
dc.identifier.pmid21864662-
dc.identifier.scopuseid_2-s2.0-80054697360en_HK
dc.identifier.hkuros204751en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80054697360&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume420en_HK
dc.identifier.issue1en_HK
dc.identifier.spage34en_HK
dc.identifier.epage42en_HK
dc.identifier.isiWOS:000296991500005-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridYamasaki, K=7402178405en_HK
dc.identifier.scopusauthoridKwok, PCL=12646007800en_HK
dc.identifier.scopusauthoridFukushige, K=54414126400en_HK
dc.identifier.scopusauthoridPrud'Homme, RK=7103032904en_HK
dc.identifier.scopusauthoridChan, HK=7403402677en_HK
dc.identifier.citeulike9694891-
dc.identifier.issnl0378-5173-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats